Agree but which shareholders will capitalize from that. Without a short term deal with enough up front cash they will need another dilution. After which they will also be closer to delisting which could result in RS. All this has a very real posssibility before any significant data could push Amgen there. If KB can land a deal then completely different story.
News 
Market Data 
Discover 
